With 1.75 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.02 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7 whereas the lowest price it dropped to was $0.6348. The 52-week range on REVB shows that it touched its highest point at $25.26 and its lowest point at $0.28 during that stretch. It currently has a 1-year price target of $12.75. Beta for the stock currently stands at 0.25.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of REVB was up-trending over the past week, with a rise of 79.19%, but this was up by 36.89% over a month. Three-month performance dropped to -21.75% while six-month performance fell -64.27%. The stock lost -95.79% in the past year, while it has gained 39.50% so far this year. A look at the trailing 12-month EPS for REVB yields -16.75 with Next year EPS estimates of -2.12. For the next quarter, that number is -0.65. This implies an EPS growth rate of -1311.32% for this year and 71.59% for next year.
Float and Shares Shorts:
At present, 8.36 million REVB shares are outstanding with a float of 8.35 million shares on hand for trading. On 2024-12-13, short shares totaled 43682.0, which was 52.0 higher than short shares on 1731628800. In addition to Mr. James M. Rolke as the firm’s CEO & Director, Mr. Chester Stanley Zygmont III serves as its CFO & Corporate Secretary.
Institutional Ownership:
Through their ownership of 0.06883 of REVB’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, REVB reported revenue of $0.0 and operating income of -$1796686.0. The EBITDA in the recently reported quarter was -$1795507.0 and diluted EPS was -$0.84.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for REVB since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With REVB analysts setting a high price target of 20.0 and a low target of 5.5, the average target price over the next 12 months is 12.75. Based on these targets, REVB could surge 3025.0% to reach the target high and rise by 759.38% to reach the target low. Reaching the average price target will result in a growth of 1892.19% from current levels.
Analysts have provided yearly estimates in a range of -$5.58 being high and -$9.38 being low. For REVB, this leads to a yearly average estimate of -$7.48.
